Sandoz decision will encourage biosimilar PTAB proceedings
The Federal Circuit’s decision in Sandoz v Amgen will lead to biosimilar companies looking to use PTAB proceedings more to invalidate drug patents, because it is now harder for them to bring district court actions before filing biosimilar applications
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: